Ports may offer easier way to deliver prostate cancer drug
NCT ID NCT06858995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether Pluvicto, a radioactive drug for prostate cancer, can be safely given through a permanently implanted port (TIVAP) instead of a standard IV. Researchers measured if any drug got stuck in the port in 107 patients. The goal was to see if using the port is a practical option for patients with difficult veins.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pluvicto (177Lu-PSMA-617)
What this could lead to
If successful, this could show that using an existing port (TIVAP) is a safe and effective way to give Pluvicto, making treatment easier for patients with poor vein access.
What could go wrong
This is a small, completed observational study, not a large trial. It only checks if the drug sticks to the port, not whether it improves treatment outcomes or survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de NANCY
Vandœuvre-lès-Nancy, 54511, France
-
Nuclear medicine Department CHRU de NANCY
Vandœuvre-lès-Nancy, 54511, France